Table 5.

Adverse events occurring in more than 5% of patients in any treatment group, irrespective of cause (safety population)^*

	Artemether-lumefantrineN = 159	Atovaquone-proguanilN = 53	Artesunate-mefloquineN = 53
Patients with AEs	46 (28.9)	25 (47.2)	36 (67.9)
Dizziness	9 (5.7)	5 (9.4)	14 (26.4)
Pyrexia	6 (3.8)	4 (7.5)	2 (3.8)
Headache	5 (3.1)	7 (13.2)	7 (13.2)
Diarrhea	3 (1.9)	2 (3.8)	7 (13.2)
Abdominal pain	3 (1.9)	2 (3.8)	4 (7.5)
Vomiting	2 (1.3)	9 (17.0)	15 (28.3)
Insomnia	0	0	4 (7.5)

^*Data are presented as n (%); AEs are listed according to decreasing frequency in the artemether-lumefantrine group.

AE = adverse event.